Johannes C. J. de Boer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Johannes C. J. de Boer has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Bas W. Raaymakers
3 shared publications- Cornel Zachiu
Radiotherapy, University Medical Centre Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, NETHERLANDS
3 shared publications - Gijsbert H. Bol
Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
3 shared publications - Cédric Draulans
Department of Oncology, KU Leuven, Leuven, Belgium; Department of Radiation Oncology, AZ Sint-Maarten Hospital, Mechelen, Belgium
2 shared publications - Floris J. Pos
Department of Radiation Oncology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands
2 shared publications - Georgios Tsekas
University Medical Center Utrecht
2 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 40
Deep learning-enhanced image registration for accelerating daily adaptive magnetic resonance imaging-guided prostate radiotherapy
- 2 August 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 40
Open AccessDeep learning-enhanced image registration for accelerating daily adaptive magnetic resonance imaging-guided prostate radiotherapy
- 27 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111608
Automated prospective quality assurance of tumor segmentation and treatment planning in the hypo-FLAME 3.0 trial
- 27 May 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 221, 111608
Automated prospective quality assurance of tumor segmentation and treatment planning in the hypo-FLAME 3.0 trial
- Open Access
- 13 September 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 36
First experimental demonstration of magnetic resonance-guided multileaf collimator tracking for (ultra-)hypofractionated prostate radiotherapy
- 13 September 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 36
Open AccessFirst experimental demonstration of magnetic resonance-guided multileaf collimator tracking for (ultra-)hypofractionated prostate radiotherapy
- Open Access
- 31 January 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 33, 100711
Added value of non-rigid image registration for intrafraction dose accumulation in magnetic resonance imaging-guided prostate radiotherapy
- 31 January 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 33, 100711
Open AccessAdded value of non-rigid image registration for intrafraction dose accumulation in magnetic resonance imaging-guided prostate radiotherapy
- Open Access
- 30 January 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 33, 100706
Dose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system
- 30 January 2025
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 33, 100706
Open AccessDose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system
- Top Cited Papers
- 1 March 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (7) , 787-796
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
PURPOSE: This study investigates whether focal boosting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localized prostate cancer. PATIENTS AND METHODS: In the phase III, multicenter, randomized controlled Focal Lesion Ablative Microboost in Prostate Cancer trial, 571 patients with intermediate- and high-risk prostate cancer were enrolled between 2009 and 2015. Patients assigned to standard treatment received 77 Gy (fractions of 2.2 Gy) to the entire prostate. The focal boost arm received an additional simultaneous integrated focal boost up to 95 Gy (fractions up to 2.7 Gy) to the intraprostatic lesion visible on multiparametric magnetic resonance imaging. Organ at risk constraints were prioritized over the focal boost dose. The primary end point was 5-year bDFS. Secondary end points were disease-free survival (DFS), distant metastases-free survival, prostate cancer-specific survival, overall survival, toxicity, and health-related quality of life. RESULTS: Median follow-up was 72 months. Biochemical DFS was significantly higher in the focal boost compared with the standard arm (hazard ratio 0.45, 95% CI, 0.28 to 0.71, P < .001). At 5-year follow-up bDFS was 92% and 85%, respectively. We did not observe differences in prostate cancer-specific survival ( P = .49) and overall survival ( P = .50). The cumulative incidence of late genitourinary and GI toxicity grade ≥ 2 was 23% and 12% in the standard arm versus 28% and 13% in the focal boost arm, respectively. Both for late toxicity as health-related quality of life, differences were small and not statistically significant. CONCLUSION: The addition of a focal boost to the intraprostatic lesion improved bDFS for patients with localized intermediate- and high-risk prostate cancer without impacting toxicity and quality of life. The Focal Lesion Ablative Microboost in Prostate Cancer study shows that a high focal boost strategy to improve tumor control while respecting organ at risk dose constraints is effective and safe.
- 1 March 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (7) , 787-796
Top Cited PapersFocal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
PURPOSE: This study investigates whether focal boosting of the macroscopic visible tumor with external beam radiotherapy increases biochemical disease-free survival (bDFS) in patients with localized prostate cancer. PATIENTS AND METHODS: In the phase III, multicenter, randomized controlled Focal Lesion Ablative Microboost in Prostate Cancer trial, 571 patients with intermediate- and high-risk prostate cancer were enrolled between 2009 and 2015. Patients assigned to standard treatment received 77 Gy (fractions of 2.2 Gy) to the entire prostate. The focal boost arm received an additional simultaneous integrated focal boost up to 95 Gy (fractions up to 2.7 Gy) to the intraprostatic lesion visible on multiparametric magnetic resonance imaging. Organ at risk constraints were prioritized over the focal boost dose. The primary end point was 5-year bDFS. Secondary end points were disease-free survival (DFS), distant metastases-free survival, prostate cancer-specific survival, overall survival, toxicity, and health-related quality of life. RESULTS: Median follow-up was 72 months. Biochemical DFS was significantly higher in the focal boost compared with the standard arm (hazard ratio 0.45, 95% CI, 0.28 to 0.71, P < .001). At 5-year follow-up bDFS was 92% and 85%, respectively. We did not observe differences in prostate cancer-specific survival ( P = .49) and overall survival ( P = .50). The cumulative incidence of late genitourinary and GI toxicity grade ≥ 2 was 23% and 12% in the standard arm versus 28% and 13% in the focal boost arm, respectively. Both for late toxicity as health-related quality of life, differences were small and not statistically significant. CONCLUSION: The addition of a focal boost to the intraprostatic lesion improved bDFS for patients with localized intermediate- and high-risk prostate cancer without impacting toxicity and quality of life. The Focal Lesion Ablative Microboost in Prostate Cancer study shows that a high focal boost strategy to improve tumor control while respecting organ at risk dose constraints is effective and safe.